Poor
Not Aligned
Patient Risk:
High
Summary
Only general pharmacologic/indication concepts are partially supported; most claims are market/regulatory/patent/regional and are not found in the provided FDA label. No FDA safety/dosing/administration sections were meaningfully addressed.
Category Scores
Accurate Statements
Diltiazem is a calcium channel blocker.
DESCRIPTION: calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist)
Diltiazem helps relax blood vessels.
CLINICAL PHARMACOLOGY (Hypertension): relaxation of vascular smooth muscle; decreases peripheral vascular resistance
Relaxation of blood vessels from diltiazem improves blood flow.
CLINICAL PHARMACOLOGY (Angina): increases coronary blood flow (epicardial and subendocardial)
Unsupported Statements
Diltiazem is used for hypertension in South and Central American nations.
Label supports hypertension indication, but provides no regional/country usage claims.
Diltiazem is used for angina in South and Central American nations.
Label supports angina indications, but provides no regional/country usage claims.
Diltiazem reduces the heart's workload.
Label supports reductions in myocardial oxygen demand/heart rate and blood pressure, but the response provides an unqualified physiologic benefit statement without matching the label’s specific context.
The availability of generic diltiazem formulations significantly influences market dynamics in South and Central America.
No corresponding content in provided label sections.
Generic versions of diltiazem are generally more affordable.
No corresponding content in provided label sections.
Generic diltiazem increases accessibility for patients and healthcare systems with limited budgets.
No corresponding content in provided label sections.
Generic diltiazem availability leads to wider adoption compared to brand-name alternatives.
No corresponding content in provided label sections.
Diltiazem pricing in South and Central America is subject to manufacturing costs.
No corresponding content in provided label sections.
Diltiazem pricing in South and Central America is subject to import duties.
No corresponding content in provided label sections.
Diltiazem pricing in South and Central America is subject to local distribution margins.
No corresponding content in provided label sections.
Diltiazem pricing in South and Central America is subject to the competitive landscape of generic manufacturers.
No corresponding content in provided label sections.
Government regulations affect the final cost of diltiazem to consumers and providers.
No corresponding content in provided label sections.
Healthcare reimbursement policies affect the final cost of diltiazem to consumers and providers.
No corresponding content in provided label sections.
Regulatory approval processes for pharmaceuticals, including diltiazem, vary by country within South and Central America.
No corresponding content in provided label sections.
Manufacturers must comply with local health authority drug registration requirements.
No corresponding content in provided label sections.
Manufacturers must comply with local health authority quality control requirements.
No corresponding content in provided label sections.
Manufacturers must comply with local health authority marketing requirements.
No corresponding content in provided label sections.
Local regulations aim to ensure the safety and efficacy of medications available to the public.
No corresponding content in provided label sections.
The diltiazem market in South and Central America includes multinational pharmaceutical companies and local generic drug manufacturers.
No corresponding content in provided label sections.
The presence of numerous generic producers contributes to competitive pricing and broad product availability across the region.
No corresponding content in provided label sections.
Patent expiries for diltiazem have largely passed in most major markets, including South and Central America.
No corresponding content in provided label sections.
As a result of patent expiries passing, generic versions of diltiazem have been available for some time in South and Central America.
No corresponding content in provided label sections.
Generic versions being available for some time contributes to widespread use and competitive pricing within the region.
No corresponding content in provided label sections.
Contradictions
Important Omissions
No FDA label information included for CONTRAINDICATIONS, WARNINGS/PRECAUTIONS, DRUG INTERACTIONS, DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS, or special populations.
Importance:
High
No dosing/administration safety details (e.g., titration/monitoring) were provided or evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response omits key FDA safety labeling content (contraindications, warnings, interactions, adverse reactions, and dosing safety). It also includes multiple non-label market/regulatory/patent claims that are not supported by FDA labeling and distract from label-based safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the response are unanchored to the provided FDA label (market/regulatory/patent/regional claims) and the response omits essential FDA safety and dosing sections.
Suggested Improvement
Restrict claims to provided FDA label content: state only label-supported indications (hypertension; chronic stable angina and angina due to coronary artery spasm) without regional/country or market assertions, and include relevant FDA safety elements (contraindications, warnings/precautions, drug interactions, and adverse reactions) when evaluating diltiazem use.